Volpe Massimo, Rosei Enrico Agabiti, Ambrosioni Ettore, Cottone Santina, Cuspidi Cesare, Borghi Claudio, De Luca Nicola, Fallo Francesco, Ferri Claudio, Morganti Alberto, Muiesan Maria Lorenza, Sarzani Riccardo, Sechi Leonardo, Virdis Agostino, Tocci Giuliano, Trimarco Bruno, Filippi Alessandro, Mancia Giuseppe
Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy.
High Blood Press Cardiovasc Prev. 2013 Mar;20(1):45-52. doi: 10.1007/s40292-013-0007-2. Epub 2013 Mar 28.
Observational clinical studies have demonstrated that only 30-40% of patients with arterial hypertension achieve the recommended blood pressure goals (below 140/90 mmHg). In contrast, interventional trials consistently showed that it is possible to achieve effective blood pressure targets in about 70% of treated hypertensive patients with different cardiovascular risk profiles, especially through the use of rational, effective and well tolerated combination therapies. In order to bridge the gap between current and desired blood pressure control and to achieve more effective prevention of cardiovascular diseases, the Italian Society of Hypertension (SIIA) has developed an interventional strategy aimed at reaching nearly 70% of treated controlled hypertensive patients by 2015. This ambitious goal can be realistically achieved by a more rational use of modern tools and supports, and also through the use of combination therapy in hypertension in daily clinical practice, especially if this approach can be simplified into a single pill (fixed combination therapy), which is a therapeutic option now also available in Italy. Since about 70-80% of treated hypertensive patients require a combination therapy based on at least two classes of drugs in order to achieve the recommended blood pressure goals, it is of key importance to implement this strategy in routine clinical practice. Amongst the various combination therapies currently available for hypertension treatment and control, the use of those strategies based on drugs that antagonize the renin-angiotensin system, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) and ACE inhibitors, in combination with diuretics and/or calcium channel blockers, has been shown to significantly reduce the risk of major cardiovascular events and to improve patient compliance to treatment, resulting in a greater antihypertensive efficacy and better tolerability compared with monotherapy. The present document of the Italian Society of Arterial Hypertension (SIIA) aims to gather the main indications for the implementation of combination therapy in the treatment of hypertension, in order to improve blood pressure control in Italy.
观察性临床研究表明,只有30%-40%的动脉高血压患者达到推荐的血压目标(低于140/90 mmHg)。相比之下,干预性试验一致表明,在约70%接受治疗的具有不同心血管风险特征的高血压患者中,尤其是通过使用合理、有效且耐受性良好的联合治疗,有可能实现有效的血压目标。为了弥合当前血压控制与理想血压控制之间的差距,并更有效地预防心血管疾病,意大利高血压学会(SIIA)制定了一项干预策略,目标是到2015年使近70%接受治疗的高血压患者血压得到控制。通过更合理地使用现代工具和支持手段,以及在日常临床实践中对高血压采用联合治疗,这个宏伟目标是可以切实实现的,特别是如果这种方法可以简化为单一药丸(固定复方制剂),而这也是目前在意大利可以采用的一种治疗选择。由于约70%-80%接受治疗的高血压患者需要基于至少两类药物的联合治疗才能达到推荐的血压目标,因此在常规临床实践中实施这一策略至关重要。在目前可用于高血压治疗和控制的各种联合治疗中,使用基于拮抗肾素-血管紧张素系统的药物的策略,如1型血管紧张素II受体拮抗剂(血管紧张素受体阻滞剂)和ACE抑制剂,与利尿剂和/或钙通道阻滞剂联合使用,已被证明可显著降低主要心血管事件的风险,并提高患者对治疗的依从性,与单一疗法相比,具有更高的降压疗效和更好的耐受性。意大利动脉高血压学会(SIIA)的本文件旨在收集高血压治疗中实施联合治疗的主要指征,以改善意大利的血压控制情况。